Given that GPER constitutes approximately up to 70% of HR+ BC and is involved in endocrine resistance through multiple mechanisms, such as somatic mutations, epigenetic and non-genetic variations, and changes within the tumor microenvironment, GPER is regarded as an optimal target for reversing endocrine resistance (Fig. 7). The gene discussed is GPER1; the disease is breast cancer.